リペラの新薬は 口腔リキーンプランスの治療に 有望な結果を示し 株価の大幅な上昇につながります Lipella's new drug shows promise in treating oral lichen planus, leading to a significant stock surge.

Lipella Pharmaceuticalsは,口腔リケーンプランスを治療する薬剤であるLP-310の第2段階a試験の結果を報告し,痛みの改善,炎症,潰瘍の改善が顕著で,深刻な副作用はありません. Lipella Pharmaceuticals has reported successful Phase 2a trial results for LP-310, a drug treating oral lichen planus, showing significant improvements in pain, inflammation, and ulceration with no serious side effects. 会社の株は,前取引で65%以上増加した. The company's stock surged over 65% in pre-market trading following the announcement. 更に高用量試験が進行中です. Further trials with higher doses are ongoing.